Growth Metrics

Moderna (MRNA) Cost of Revenue (2020 - 2026)

Moderna (MRNA) has disclosed Cost of Revenue for 7 consecutive years, with $955.0 million as the latest value for Q1 2026.

  • For Q1 2026, Cost of Revenue rose 961.11% year-over-year to $955.0 million; the TTM value through Mar 2026 reached $1.7 billion, up 18.86%, while the annual FY2025 figure was $868.0 million, 40.71% down from the prior year.
  • Cost of Revenue hit $955.0 million in Q1 2026 for Moderna, up from $452.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $2.2 billion in Q3 2023 and bottomed at $90.0 million in Q1 2025.
  • Average Cost of Revenue over 5 years is $698.7 million, with a median of $731.0 million recorded in 2023.
  • Year-over-year, Cost of Revenue plummeted 87.88% in 2024 and then surged 961.11% in 2026.
  • Moderna's Cost of Revenue stood at $400.0 million in 2022, then soared by 132.25% to $929.0 million in 2023, then fell by 20.45% to $739.0 million in 2024, then tumbled by 38.84% to $452.0 million in 2025, then soared by 111.28% to $955.0 million in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $955.0 million, $452.0 million, and $207.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.